Full Title: Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
Introduction
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, Datamonitor forecasts the market to grow to over $2.4 billion in 2017.
Scope
Analysis of clinical trial design and treatment guidelines in fibromyalgia.
Fibromyalgia market sizing assessment with detailed methodology.
Detailed profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.
Case study analysis of Pfizer’s launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.
Highlights
The approval of Pfizer’s Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.In June 2008, Eli Lilly’s dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Datamonitor forecasts seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.
Reasons to Purchase
Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.
Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.
Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs.
